SUBSCRIBE
SUBSCRIBE
News   Drug Development

Vectura Group plc Announces Successful Outcome Of Phase II Study On Inhaled Parkinson’s Disease Product – VR040

August 8, 2006 | 
1 min read
Vectura Group plc (LSE: VEC) (“Vectura”) today announces the successful outcome of a Phase II “proof-of concept” clinical study for its product, VR040, for the treatment of induced “off” periods in patients with Parkinson’s disease (PD).
Clinical research Phase 2 Europe
MORE ON THIS TOPIC
Rocket rising moving up with growthing graph bar. Marketing time, Start up business, Business success strategy, New project. Rocket launch. Business startup concept. 3d minimal render illustration
GLP-1
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
July 28, 2026
 · 
3 min read
 · 
Tristan Manalac
Laptop with envelope and document with exclamation mark on screen. Receive notification, alert message, warning, get e-mail, email, spam concepts. Flat design vector illustration
FDA
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy
July 27, 2026
 · 
3 min read
 · 
Heather McKenzie
Stacked person head silhouettes. Abstract painting.
Neuroscience
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
July 27, 2026
 · 
2 min read
 · 
Michael Gibney
3D Paper Cut Pair of Lung dotted with yellow tumor bacteria infection spread across on a blue background with no text. Yellow dots as virus infection in the lungs. Vector Illustration.
Business
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
July 27, 2026
 · 
3 min read
 · 
Gabrielle Masson